23 24 Mycobacterium abscessus is responsible of a wide spectrum of clinical syndromes and is one of 25 the most intrinsically drug-resistant mycobacterial species. Recent evaluation of the in vivo 26 therapeutic efficacy of the few potentially active antibiotics against M. abscessus was 27 essentially performed using immune-compromised mice. Herein, we assessed the feasibility 28 and sensitivity of fluorescence imaging for monitoring the in vivo activity of drugs against acute 29 M. abscessus infection using zebrafish embryos. A protocol was developed where 30 clarithromycin and imipenem were directly added to water containing fluorescent M. 31 abscessus-infected embryos in a 96-well plate format. The status of the infection with 32 increasing drug concentrations was visualized on a spatiotemporal level. Drug efficacy was 33 assessed quantitatively by determining the index of protection, the bacterial burden by CFU 34 plating and by monitoring the number of abscesses through fluorescence measurements. Both 35 drugs were active in infected embryos and were capable of significantly increasing embryo 36 survival in a dose-dependent manner. Protection from bacterial killing correlated with 37 restricted mycobacterial growth in the drug-treated larvae and with reduced pathophysiological 38 symptoms, such as the number of abscesses within the brain. In conclusion, we present here a 39 new and efficient method for testing and compare the in vivo activity of two clinically-relevant 40 drugs based on a fluorescent reporter strain in zebrafish embryos. This approach could be 41 applied to a rapid determination of in vivo drug susceptibility profile of clinical isolates and to 42 assess the preclinical efficacy of new compounds against M. abscessus.
INTRODUCTION 45 46 M. abscessus (Mabs) is an emerging pathogen and the etiological agent of a wide spectrum 47 of infections in humans. It is responsible for severe chronic pulmonary and disseminated 48 infections, mostly in immunosuppressed and in cystic fibrosis (CF) patients (1), and cutaneous 49 diseases, often post-traumatic and post-surgical. This neglected pathogen causes a higher 50 fatality rate compared to other RGMs and the infection of CF patients is becoming a major 51 health-related issue in most CF centers worldwide (2). Mabs infections occur in early childhood 52 (3), are severe and sometimes fatal, especially following transplantation (4-6), and have the 53 potential to cause outbreaks of infection (6) . Mabs is also the main RGM responsible for 54 nosocomial and iatrogenic infections in humans (post-injection abscesses, cardiac surgery, and 55 plastic surgery) (7-9). It has also been reported to cross the blood-brain barrier and to cause 56 important central nervous system (CNS) lesions. Although a rapid grower, Mabs possesses 57 several important pathogenic traits such as the ability to i) persist silently for years and even 58 decades (10) in the human host, and to ii) induce lung disease associated with caseous lesions 59 and granuloma formation in lung parenchyma (11, 12) . 60 The major issue with Mabs relies on its intrinsic resistance to the majority of available 61 antibiotics. The American Thoracic Society has recommended different groups of agents, 62 namely macrolides (clarithromycin), aminoglycosides (amikacin), cephamycins (cefoxitin) and 63 carbapenems (imipenem) for treatment of Mabs infections (13). Patients with severe infections 64 are generally treated with long courses of combinatorial antibiotic therapy, often accompanied 65 by surgical resection. As antibiotic susceptibility testing is not fully standardized, the clinical 66 response to drugs does not correlate well with in vitro susceptibility test results and failure 67 occurs frequently despite administration of two or three antibiotics for several months (14) . 68 4 This further emphasizes the need of suitable animal models (15, 16) . In addition, different 69 clinical isolates of this emerging pathogen are not uniformly susceptible to the currently used 70 antibiotics (17). As a consequence, an optimal regimen to cure the Mabs infections has not 71 been yet established. 72 Thanks to the recent availability of efficient genetic tools (18), Mabs has been proposed as 73 an attractive experimental model to study non-tuberculous mycobacteria associated diseases 74 (1). Our poor understanding of the pathogenesis of infection foci/abscesses within the CNS, particularly the brain, appear very rapidly and are very 81 easy to detect and visualize, we reasoned that this alternative model could represent a valuable 82 and cheap system to evaluate and compare the in vitro and in vivo activity of drugs against 83 Mabs. Such a simple and innovative system would be particularly suited for screening active 84 molecules and/or antibacterial activity assessment, representing a critical step in the context of 85 drug discovery, urgent in the case of Mabs. 86 Here, we report on the development of experimental conditions for in vivo imaging of 87 Mabs and demonstrate that it is compatible with in vivo observations, at a spatiotemporal 88 level, of the effects of drug treatment on the infection process. This represents a unique 89 biological model that allows non-invasive observations to evaluate, in real time, the efficacy of 90 antibiotics in living infected vertebrates, a system that could be applied to high-throughput in 91 vivo testing of drug efficacy against the most drug-resistant mycobacterial species. 96 The rough variant of M. abscessus sensu stricto strain CIP104536 T on the values determined using the microdilution method (Table S1 ). In vivo drug efficacy was 157 determined for each concentration by following i) the bacterial burdens, ii) the kinetic of ). This shows that clarithromycin, using the highest regimen, is efficient in the ZF test system.
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Effects of clarithromycin on ZF survival, bacterial burden and abscesses 262
Increased survival was associated with lower bacterial burdens after 3dpi in the presence 263 of the highest dose (170X MIC), as determined quantitatively by CFU plating ( Figure 3C ), 264 whereas treatment with the low or intermediate doses failed to restrict mycobacterial growth. 265 In vivo drug efficacy was next monitored by time-lapse fluorescence microscopy ( Figure 3D ). 266 Injection of Mabs led to the appearance of rapidly growing infection foci and abscesses in the 267 larval brain at 3dpi, as reported previously (19). Imaging the same infected embryos at 3 and 268 5dpi revealed that abscesses within the brain were already reduced at 3dpi when treated with Figure 4D) , 297 a phenotypic effect that was particularly apparent in the brain on infected embryos ( Figure 4E ), 298 indicating that imipenem reduces the pathology signs of the infection. 299 These results also prompted us to examine whether imipenem can counteract/alter the 300 progression of an already established infection, especially when given at 3dpi when brain 301 abscesses are already apparent ( Figure S1A ). Death curves indicate that treatment with high 302 doses of imipenem effectively extended the life span of embryos with pre-existing abscesses 303 ( Figure S1B ). A large proportion (more than 60%) of the treated embryos survived to the 304 infection compared to 10% for the non-treated individuals (P=0.008). The remaining 40% 305 embryos that died despite the treatment showed increased bacterial loads in the CNS (data not 306 shown). The increased index of protection rate was associated to a significant decrease in the 307 number of embryos with abscesses ( Figure S1C ), particularly within the brain ( Figure S1D ). This 308 14 "curative" protocol shows that imipenem was able to cure embryos with pre-existing abscesses 309 and to protect severely infected ZF. are easy to visualize and to numerate by fluorescence microscopy ( Figure 5A ), and because they 318 promote extracellular replication, abscess formation and tissue damage, we investigated 319 whether exposure of infected embryos to imipenem may also affect the development of 320 mycobacterial cords. Figure 5B shows the presence of multiple cords within the brain at 5dpi 321 (left panel) and the impact of imipenem treatment on the number of cords (right panel). 322 Quantitative analysis of the percentage of embryos with cords at 4dpi is shown in Figure   323 5C. The presence of low doses of imipenem has little impact on mycobacterial cords, although a 324 reduction of the number of embryos with cords was detected at 4dpi. However, this effect was 325 more pronounced with higher drug concentrations with only 20% of cord-laden embryos at 326 4dpi (compared to 60% for untreated embryos at 4dpi). This dose-dependent effect occurred 327 essentially within the CNS whilst reduction of cord formation within the vasculature was not 328 significant ( Figure 5D ). ACKNOWLEDGMENTS 421 We thank L. Ramakrishnan for the generous gift of pTEC27 and for helpful discussions and the 422 Montpellier RIO Imaging and the SCME facilities at UM2. 423 This study was supported by the french National Research Agency (http://www.agence- infected with ≈300 CFU of Mabs expressing dtTomato and distributed and incubated into 96-wells plate (1). From 1dpi, embryos were exposed to the drugs of interest which were directly added to the wells. Drugs are then removed and daily renewed for 5 days (2). To determinate the in vivo antibacterial effects of the drugs, the embryo survival, the bacterial loads and the evolution of the infection process were monitored at a spatiotemporal level by videomicroscopy (3). 
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